A Pharmaceutical company called Vivus is hoping to launch an erectile dysfunction drug called avanafil. Vivus issued a press release stating that there new drug Avanafil will be much faster than Viagra Cialis & Levitra.
Mr Leland Wilson, chief executive officer of VIVUS stated "Erectile dysfunction is a significant problem among more than half of all men over the age of 40. While sales of currently available ED therapies exceed $3.8 billion a year, persistent switching by patients suggests that patients are less than satisfied with current therapies," "These phase 3 avanafil data not only confirm the robust efficacy we've seen in earlier trials, but potentially differentiate avanafil from other PDE5 inhibitors when it comes to side effects and time-to-onset of efficacy. We are confident that avanafil can effectively compete in the oral ED therapy market."
Mr Charles Bowden, M.D., Senior Director, Clinical Development at VIVUS stated "From our discussions with patients and physicians, we knew that rapid onset was an important attribute in the selection of an ED therapy. A recent study in 1,900 patients with ED showed that 75% of patients identified rapid effect as an important treatment expectation. Knowing that avanafil can be effective within 15 minutes should create an attractive position in the PDE5 market,"
Existing erectile dysfunction medication tends to work after 30 minutes and therefore this would make Avanafil’s shorter effective medication of 15 minutes quite popular.
Medical Specialists News will be looking out for any updates regarding the new Avanafil erectile dysfunction medication.
Mr Leland Wilson, chief executive officer of VIVUS stated "Erectile dysfunction is a significant problem among more than half of all men over the age of 40. While sales of currently available ED therapies exceed $3.8 billion a year, persistent switching by patients suggests that patients are less than satisfied with current therapies," "These phase 3 avanafil data not only confirm the robust efficacy we've seen in earlier trials, but potentially differentiate avanafil from other PDE5 inhibitors when it comes to side effects and time-to-onset of efficacy. We are confident that avanafil can effectively compete in the oral ED therapy market."
Mr Charles Bowden, M.D., Senior Director, Clinical Development at VIVUS stated "From our discussions with patients and physicians, we knew that rapid onset was an important attribute in the selection of an ED therapy. A recent study in 1,900 patients with ED showed that 75% of patients identified rapid effect as an important treatment expectation. Knowing that avanafil can be effective within 15 minutes should create an attractive position in the PDE5 market,"
Existing erectile dysfunction medication tends to work after 30 minutes and therefore this would make Avanafil’s shorter effective medication of 15 minutes quite popular.
Medical Specialists News will be looking out for any updates regarding the new Avanafil erectile dysfunction medication.
No comments:
Post a Comment